BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
9.90
-0.18 (-1.79%)
At close: Sep 5, 2025, 4:00 PM
10.23
+0.33 (3.33%)
After-hours: Sep 5, 2025, 7:59 PM EDT
BBOT Stock Forecast
Stock Price Forecast
The 2 analysts that cover BBOT stock have a consensus rating of "Buy" and an average price target of $24, which forecasts a 142.42% increase in the stock price over the next year. The lowest target is $23 and the highest is $25.
Price Target: $24 (+142.42%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BBOT stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 |
|---|---|
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $23 | Buy | Initiates | $23 | +132.32% | Sep 4, 2025 |
| Wedbush | Wedbush | Buy Initiates $25 | Buy | Initiates | $25 | +152.53% | Aug 18, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
from -511.80
EPS Next Year
n/a
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.